Omega Diagnostics (AIM: ODX) interim results showed the core business to be nudging in the right direction. Food intolerance testing is performing particularly well with sales up by 20 percent. This is being partially offset by a tougher market for allergy where there’s an ongoing decline in German sales. In round numbers the outlook is for a broadly flat year in profit terms. But there are a few things happening within Omega that suggest the shares are worth a further look.